125 related articles for article (PubMed ID: 21239165)
1. Prognostic value of axillary lymph node status after neoadjuvant chemotherapy. Results from a multicentre study.
Saxena N; Hartman M; Aziz R; Rapiti E; Bhoo Pathy N; Lim SE; Iau P; Taib NA; Schaffar R; Neyroud-Caspar I; Yip CH; Lee SC; Verkooijen HM
Eur J Cancer; 2011 May; 47(8):1186-92. PubMed ID: 21239165
[TBL] [Abstract][Full Text] [Related]
2. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
3. Lymph node ratio as an alternative to pN staging in node-positive breast cancer.
Vinh-Hung V; Verkooijen HM; Fioretta G; Neyroud-Caspar I; Rapiti E; Vlastos G; Deglise C; Usel M; Lutz JM; Bouchardy C
J Clin Oncol; 2009 Mar; 27(7):1062-8. PubMed ID: 19164210
[TBL] [Abstract][Full Text] [Related]
4. Lymph Node Ratio Analysis After Neoadjuvant Chemotherapy is Prognostic in Hormone Receptor-Positive and Triple-Negative Breast Cancer.
Tsai J; Bertoni D; Hernandez-Boussard T; Telli ML; Wapnir IL
Ann Surg Oncol; 2016 Oct; 23(10):3310-6. PubMed ID: 27401442
[TBL] [Abstract][Full Text] [Related]
5. Using the Lymph Node Ratio to Evaluate the Prognosis of Stage II/III Breast Cancer Patients Who Received Neoadjuvant Chemotherapy and Mastectomy.
Wu SG; Li Q; Zhou J; Sun JY; Li FY; Lin Q; Lin HX; Gaun XX; He ZY
Cancer Res Treat; 2015 Oct; 47(4):757-64. PubMed ID: 25672578
[TBL] [Abstract][Full Text] [Related]
6. Lymph node ratio and pN staging in patients with node-positive breast cancer: a report from the Korean breast cancer society.
Ahn SH; Kim HJ; Lee JW; Gong GY; Noh DY; Yang JH; Jung SS; Park HY
Breast Cancer Res Treat; 2011 Nov; 130(2):507-15. PubMed ID: 21858659
[TBL] [Abstract][Full Text] [Related]
7. Impact of Lymph Node Ratio on Oncologic Outcomes in ypStage III Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy followed by Total Mesorectal Excision, and Postoperative Adjuvant Chemotherapy.
Koo T; Song C; Kim JS; Kim K; Chie EK; Kang SB; Lee KW; Kim JH; Jeong SY; Kim TY
PLoS One; 2015; 10(9):e0138728. PubMed ID: 26381522
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of lymph node ratio in stage III colorectal cancer.
Wong KP; Poon JT; Fan JK; Law WL
Colorectal Dis; 2011 Oct; 13(10):1116-22. PubMed ID: 20874800
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA
Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929
[TBL] [Abstract][Full Text] [Related]
10. Lymph node counts and ratio in axillary dissections following neoadjuvant chemotherapy for breast cancer: a better alternative to traditional pN staging.
Chen S; Liu Y; Huang L; Chen CM; Wu J; Shao ZM
Ann Surg Oncol; 2014 Jan; 21(1):42-50. PubMed ID: 24013900
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Cho N; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
Breast Cancer Res Treat; 2009 Jul; 116(1):153-60. PubMed ID: 18787948
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study.
Kim SH; Jung KH; Kim TY; Im SA; Choi IS; Chae YS; Baek SK; Kang SY; Park S; Park IH; Lee KS; Choi YJ; Lee S; Sohn JH; Park YH; Im YH; Ahn JH; Kim SB; Kim JH
Cancer Res Treat; 2016 Oct; 48(4):1373-1381. PubMed ID: 27034147
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of lymph node ratio in node-positive breast cancer: a Dutch nationwide population-based study.
Dings PJ; Elferink MA; Strobbe LJ; de Wilt JH
Ann Surg Oncol; 2013 Aug; 20(8):2607-14. PubMed ID: 23536053
[TBL] [Abstract][Full Text] [Related]
14. Lymph node ratio: a new feature for defining risk category of node-positive breast cancer patients.
Yang C; Liu F; Li S; Li W; Zhai L; Ren M; Li Y; Lang R; Fan Y; Zhang X; Fu L
Int J Surg Pathol; 2012 Dec; 20(6):546-54. PubMed ID: 22736300
[TBL] [Abstract][Full Text] [Related]
15. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
Decaluwé H; De Leyn P; Vansteenkiste J; Dooms C; Van Raemdonck D; Nafteux P; Coosemans W; Lerut T
Eur J Cardiothorac Surg; 2009 Sep; 36(3):433-9. PubMed ID: 19502079
[TBL] [Abstract][Full Text] [Related]
16. Lymph node ratio should be considered for incorporation into staging for breast cancer.
Chagpar AB; Camp RL; Rimm DL
Ann Surg Oncol; 2011 Oct; 18(11):3143-8. PubMed ID: 21847696
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of residual nodal burden using lymph node ratio in locally advanced breast cancer after neoadjuvant chemotherapy.
Agarwal R; Philip A; Pavithran K; Rajanbabu A; Goel G; Vijaykumar DK
Indian J Cancer; 2019; 56(3):228-235. PubMed ID: 31389386
[TBL] [Abstract][Full Text] [Related]
18. Lymph node ratio is an independent prognostic factor in patients with rectal cancer treated with preoperative chemoradiotherapy and curative resection.
Lee SD; Kim TH; Kim DY; Baek JY; Kim SY; Chang HJ; Park SC; Park JW; Oh JH; Jung KH
Eur J Surg Oncol; 2012 Jun; 38(6):478-83. PubMed ID: 22465588
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer.
Pierga JY; Mouret E; Diéras V; Laurence V; Beuzeboc P; Dorval T; Palangié T; Jouve M; Vincent-Salomon A; Scholl S; Extra JM; Asselain B; Pouillart P
Br J Cancer; 2000 Dec; 83(11):1480-7. PubMed ID: 11076657
[TBL] [Abstract][Full Text] [Related]
20. Lymph node ratio as best prognostic factor in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy.
De la Cruz-Ku GA; Chambergo-Michilot D; Valcarcel B; Rebaza P; Möller M; Araujo JM; Enriquez D; Morante Z; Razuri C; Luque R; Saavedra A; Eyzaguirre E; Lujan M; Noel N; Pinto J; Cotrina J; Gomez H
Breast J; 2020 Sep; 26(9):1659-1666. PubMed ID: 32713113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
